ZA200400481B - Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions. - Google Patents
Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions. Download PDFInfo
- Publication number
- ZA200400481B ZA200400481B ZA200400481A ZA200400481A ZA200400481B ZA 200400481 B ZA200400481 B ZA 200400481B ZA 200400481 A ZA200400481 A ZA 200400481A ZA 200400481 A ZA200400481 A ZA 200400481A ZA 200400481 B ZA200400481 B ZA 200400481B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- prophylaxis
- pharmaceutical composition
- disease
- diseases
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 21
- 230000003920 cognitive function Effects 0.000 title claims description 16
- 230000007423 decrease Effects 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 24
- 230000003340 mental effect Effects 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000011321 prophylaxis Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- QOBGWWQAMAPULA-RLLQIKCJSA-N n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 QOBGWWQAMAPULA-RLLQIKCJSA-N 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 6
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical class C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241001465754 Metazoa Species 0.000 description 14
- 229950011405 deramciclane Drugs 0.000 description 10
- 230000035939 shock Effects 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007787 long-term memory Effects 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- -1 hydrogen halides Chemical class 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical group C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000028252 learning or memory Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0103017A HUP0103017A3 (en) | 2001-07-18 | 2001-07-18 | Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200400481B true ZA200400481B (en) | 2005-01-24 |
Family
ID=90001562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200400481A ZA200400481B (en) | 2001-07-18 | 2004-01-22 | Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040171696A1 (de) |
| EP (1) | EP1408940B1 (de) |
| JP (1) | JP2004537548A (de) |
| KR (1) | KR20040017326A (de) |
| CN (1) | CN1545410A (de) |
| AT (1) | ATE408403T1 (de) |
| CA (1) | CA2453834A1 (de) |
| CZ (1) | CZ200460A3 (de) |
| DE (1) | DE60228968D1 (de) |
| EA (1) | EA006897B1 (de) |
| HU (1) | HUP0103017A3 (de) |
| IL (1) | IL159841A0 (de) |
| PL (1) | PL365258A1 (de) |
| RS (1) | RS4904A (de) |
| SK (1) | SK312004A3 (de) |
| UA (1) | UA78714C2 (de) |
| WO (1) | WO2003007926A2 (de) |
| ZA (1) | ZA200400481B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0301537A3 (en) * | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
| HUP0301906A3 (en) * | 2003-06-23 | 2006-03-28 | Egis Gyogyszergyar Nyilvanosan | Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity |
| EP1500391A1 (de) * | 2003-07-24 | 2005-01-26 | Neuro3D | Medizinische Verwendung von Bicycloheptan-Derivaten |
| CN1946386A (zh) * | 2004-03-12 | 2007-04-11 | 埃吉斯药物工厂 | 作为镇痛药的德伦环烷和阿片类的组合 |
| US20080021016A1 (en) * | 2004-03-12 | 2008-01-24 | Levay Gyoergy | Combined Pharmaceutical Composition for the Inhibition of the Decline of Cognitive Functions |
| KR101642113B1 (ko) | 2014-10-08 | 2016-07-25 | 원광대학교산학협력단 | 퇴행성 뇌질환을 예방, 개선 또는 치료하는 유황의 법제 방법 및 상기 방법으로 법제된 유황 |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU179164B (en) * | 1979-12-14 | 1982-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing cycloalkyl-ethers of alkanolamines |
| HU226061B1 (en) * | 1996-10-17 | 2008-04-28 | Egis Gyogyszergyar Nyilvanosan | 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation |
| HU227114B1 (en) * | 1999-05-11 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
-
2001
- 2001-07-18 HU HU0103017A patent/HUP0103017A3/hu unknown
-
2002
- 2002-07-18 EP EP02745700A patent/EP1408940B1/de not_active Expired - Lifetime
- 2002-07-18 KR KR10-2004-7000792A patent/KR20040017326A/ko active IP Right Grant
- 2002-07-18 UA UA2004021167A patent/UA78714C2/uk unknown
- 2002-07-18 PL PL02365258A patent/PL365258A1/xx not_active Application Discontinuation
- 2002-07-18 DE DE60228968T patent/DE60228968D1/de not_active Expired - Fee Related
- 2002-07-18 IL IL15984102A patent/IL159841A0/xx unknown
- 2002-07-18 JP JP2003513535A patent/JP2004537548A/ja active Pending
- 2002-07-18 SK SK31-2004A patent/SK312004A3/sk not_active Application Discontinuation
- 2002-07-18 CA CA002453834A patent/CA2453834A1/en not_active Abandoned
- 2002-07-18 CN CNA028163729A patent/CN1545410A/zh active Pending
- 2002-07-18 US US10/483,808 patent/US20040171696A1/en not_active Abandoned
- 2002-07-18 AT AT02745700T patent/ATE408403T1/de not_active IP Right Cessation
- 2002-07-18 CZ CZ200460A patent/CZ200460A3/cs unknown
- 2002-07-18 WO PCT/HU2002/000069 patent/WO2003007926A2/en active IP Right Grant
- 2002-07-18 EA EA200400192A patent/EA006897B1/ru not_active IP Right Cessation
- 2002-07-18 RS YU4904A patent/RS4904A/sr unknown
-
2004
- 2004-01-22 ZA ZA200400481A patent/ZA200400481B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ200460A3 (cs) | 2004-05-12 |
| EA006897B1 (ru) | 2006-04-28 |
| CN1545410A (zh) | 2004-11-10 |
| IL159841A0 (en) | 2004-06-20 |
| KR20040017326A (ko) | 2004-02-26 |
| PL365258A1 (en) | 2004-12-27 |
| ATE408403T1 (de) | 2008-10-15 |
| HUP0103017D0 (en) | 2001-10-28 |
| WO2003007926A2 (en) | 2003-01-30 |
| DE60228968D1 (de) | 2008-10-30 |
| SK312004A3 (en) | 2004-06-08 |
| EP1408940A2 (de) | 2004-04-21 |
| WO2003007926A3 (en) | 2003-09-18 |
| RS4904A (en) | 2006-10-27 |
| JP2004537548A (ja) | 2004-12-16 |
| HUP0103017A3 (en) | 2004-05-28 |
| US20040171696A1 (en) | 2004-09-02 |
| CA2453834A1 (en) | 2003-01-30 |
| HUP0103017A2 (hu) | 2003-07-28 |
| EP1408940B1 (de) | 2008-09-17 |
| EA200400192A1 (ru) | 2004-06-24 |
| UA78714C2 (en) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240156811A1 (en) | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder | |
| US20030049272A1 (en) | Pharmaceutical composition which produces irritation | |
| WO2006053067A2 (en) | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders | |
| CA2893468C (en) | Use of vortioxetine and donepezil in the treatment of cognitive impairment | |
| US8461146B2 (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
| KR101477043B1 (ko) | 디스키네시아의 치료 또는 예방제 | |
| EP1408940B1 (de) | Deramciclan-enthaltende pharmazeutische zusammensetzung für die behandlung der verringerung kognitiver funktionen und/oder schäden davon | |
| CZ296282B6 (cs) | Farmaceutický prostredek | |
| IE843149L (en) | Synergistic pharmaceutical compositions | |
| RU2387446C2 (ru) | 1-фенил-2-диметиламинометилциклогексановые соединения для лечения депрессий и боли | |
| AU2002317412A1 (en) | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions | |
| US20090124606A1 (en) | Composition for Treatment of Psychosis | |
| UA81052C2 (en) | Use of bicyclo [2.2.1] heptane derivatives for the preparation of neuroprotective pharmaceutical compositions for the reduction of the consequences of ischemic or traumatic brain and spinal damage | |
| US6589996B2 (en) | Treatment of disorders relating to the serotonergic system | |
| CZ20023025A3 (cs) | Léčba chorob vztahujících se k serotonergnímu systému | |
| KR20220108123A (ko) | 치매 환자의 행동 및 심리적 증상 치료 | |
| WO2024026480A1 (en) | Compositions and methods for prevention of cognitive decline caused by degenerative diseases | |
| NZ523812A (en) | Medicaments containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient for treating dementia, dsmnesia, learning deficit and higher brain dysfunction | |
| WO2002043727A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives | |
| NZ715951B2 (en) | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders | |
| NZ203632A (en) | Pharmaceutical compositions containing certain 5-(3-aminopropylidene)-dibenzocycloheptadiene derivatives and codergocrine |